To prevent the rejection of newly transplanted organs and cells, patients must take medicines that weaken their entire immune systems. Such potentially life-saving treatments can, paradoxically, leave those receiving them susceptible to life-threatening infections.

University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.

A new discovery by London biologists may yield new ways of handling the problem of transplant rejection. In a research article published in the November 2008 print issue of The FASEB Journal, the scientists confirm the two-way transfer of a molecule (called "MHC") that instructs the immune system to tell "self" from "non-self."

UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.

Southwestern Medical Center researchers, collaborating with colleagues in Germany, have for the first time identified antibodies associated with transplant rejection of otherwise healthy kidneys.